Effect of delayed cerebral vasospasm on cerebrovascular endothelin A receptor expression and function

Journal of Neurosurgery

Volumn 107, Issue 1, 2007, Pages 121-127

  Vatter, Hartmut ^a,c   Konczalla, Juergen ^a   Weidauer, Stefan ^a   Preibisch, Christine ^a   Zimmermann, Michael ^b   Raabe, Andreas ^a   Seifert, Volker ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Hospital Duisburg North   (Germany)

^c NONE   (Germany)

Author keywords

Basilar artery; Cerebral vasospasm; Clazosentan; Double hemorrhage model; Endothelin; Endothelin A receptor; Rat

Indexed keywords

CLAZOSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASILAR ARTERY; BRAIN BLOOD VESSEL; BRAIN VASOSPASM; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; ENDOTHELIUM; FORCE; IMMUNOHISTOCHEMISTRY; ISOMETRICS; MALE; NONHUMAN; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SMOOTH MUSCLE; STAINING; SUBARACHNOID HEMORRHAGE;

ANIMALS; BASILAR ARTERY; DIOXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOHISTOCHEMISTRY; ISOMETRIC CONTRACTION; MAGNETIC RESONANCE IMAGING; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PYRIDINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; SUBARACHNOID HEMORRHAGE; SULFONAMIDES; TETRAZOLES; TIME FACTORS; VASOSPASM, INTRACRANIAL;

EID: 34347377573     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/JNS-07/07/0121     Document Type: Article

References (37)

1. Alabadi JA, Torregrosa G, Miranda FJ, Salom JB, Centeno JM, Alborch E: Impairment of the modulatory role of nitric oxide on the endothelin-1-elicited contraction of cerebral arteries: a pathogenetic factor in cerebral vasospasm after subarachnoid hemorrhage? Neurosurgery 41:245-253, 1997
2. Alafaci C, Jansen I, Arbab MA, Shiokawa Y, Svendgaard NA, Edvinsson L: Enhanced vasoconstrictor effect of endothelin in cerebral arteries from rats with subarachnoid haemorrhage. Acta Physiol Scand 138:317-319, 1990
3. Beck J, Raabe A, Lanfermann H, Seifert V, Weidauer S: Tissue at risk concept for endovascular treatment of severe vasospasm after aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 75:1779-1781, 2004
4. Callera GE, Montezano AC, Touyz RM, Zorn TM, Carvalho MH, Fortes ZB, et al: ETA receptor mediates altered leukocyte-endothelial cell interaction and adhesion molecules expression in DOCA-salt rats. Hypertension 43:872-879, 2004
5. Chow M, Dumont AS, Kassell NF: Endothelin receptor antagonists and cerebral vasospasm: an update. Neurosurgery 51:1333-1342, 2002
6. Dumont AS, Dumont RJ, Chow MM, Lin CL, Calisaneller T, Ley KF, et al: Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation. Neurosurgery 53:123-135, 2003
7. Ehrenreich H, Schilling L: New developments in the understanding of cerebral vasoregulation and vasospasm: the endothelin-nitric oxide network. Cleve Clin J Med 62:105-116, 1995
8. Feger GI, Schilling L, Ehrenreich H, Wahl M: Endothelium-dependent relaxation counteracting the contractile action of endothelin-1 is partly due to ETB receptor activation. Res Exp Med (Berl) 196:327-337, 1997
9. Findlay JM, Deagle GM: Causes of morbidity and mortality following intracranial aneurysm rupture. Can J Neurol Sci 25:209-215, 1998
10. Hansen-Schwartz J, Hoel NL, Zhou M, Xu CB, Svendgaard NA, Edvinsson L: Subarachnoid hemorrhage enhances endothelin receptor expression and function in rat cerebral arteries. Neurosurgery 52:1188-1195, 2003
11. Hertel F, Walter C, Bettag M, Morsdorf M: Perfusion-weighted magnetic resonance imaging in patients with vasospasm: a useful new tool in the management of patients with subarachnoid hemorrhage. Neurosurgery 56:28-35, 2005
12. Hino A, Tokuyama Y, Kobayashi M, Yano M, Weir B, Takeda J, et al: Increased expression of endothelin B receptor mRNA following subarachnoid hemorrhage in monkeys. J Cereb Blood Flow Metab 16:688-697, 1996
13. Hop JW, Rinkel GJ, Algra A, van Gijn J: Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Stroke 28:660-664, 1997
14. Itoh S, Sasaki T, Asai A, Kuchino Y: Prevention of delayed vasospasm by an endothelin ETA receptor antagonist, BQ-123: change of ETA receptor mRNA expression in a canine subarachnoid hemorrhage model. J Neurosurg 81:759-764, 1994
15. Konczalla J, Vatter H, Weidauer S, Raabe A, Seifert V: Alteration of the cerebrovascular function of endothelin B receptor after subarachnoidal hemorrhage in the rat. Exp Biol Med (Maywood) 231:1064-1068, 2006
16. Macdonald RL: Management of cerebral vasospasm. Neurosurg Rev 29:179-193, 2006
17. Macdonald RL, Kakarieka A, Mayer S, Pasqualin D, Ruefenacht D, Schmiedek P, et al: Prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage with clazosentan, an endothelin receptor antagonist, in 9th International Conference on Cerebral Vasospasm. June 27-30, 2006, Istanbul Turkey, The Marmara Hotel. Abstract Book, 2006 (Abstract OP5-3)
18. Macdonald RL, Zhang ZD, Takahashi M, Nikitina E, Young J, Xie A, et al: Calcium sensitivity of vasospastic basilar artery after experimental subarachnoid hemorrhage. Am J Physiol Heart Circ Physiol 290:H2329-H2336, 2006
19. Masaki T: Historical review: Endothelin. Trends Pharmacol Sci 25:219-224, 2004
20. Rabinstein AA, Pichelmann MA, Friedman JA, Piepgras DG, Nichols DA, McIver JI, et al: Symptomatic vasospasm and outcomes following aneurysmal subarachnoid hemorrhage: a comparison between surgical repair and endovascular coil occlusion. J Neurosurg 98:319-325, 2003
21. Rordorf G, Koroshetz WJ, Copen WA, Gonzalez G, Yamada K, Schaefer PW, et al: Diffusion- and perfusion-weighted imaging in vasospasm after subarachnoid hemorrhage. Stroke 30:599-605, 1999
22. Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, et al: Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 283:1110-1118, 1997
23. Roux S, Loffler BM, Gray GA, Sprecher U, Clozel M, Clozel JP: The role of endothelin in experimental cerebral vasospasm. Neurosurgery 37:78-86, 1995
24. Rubanyi GM, Polokoff MA: Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46:325-415, 1994
25. Salom JB, Torregrosa G, Alborch E: Endothelins and the cerebral circulation. Cerebrovasc Brain Metab Rev 7:131-152, 1995
26. Schilling L, Vatter H, Mursch K, Ehrenreich H, Schmiedek P: Characterization of the contractile and relaxant action of the endothelin-1 precursor, big endothelin-1, in the isolated rat basilar artery. Peptides 21:91-99, 2000
27. Solenski NJ, Haley EC Jr, Kassell NF, Kongable G, Germanson T, Truskowski L, et al: Medical complications of aneurysmal subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants of the Multicenter Cooperative Aneurysm Study. Crit Care Med 23:1007-1017, 1995
28. Solomon RA, Antunes JL, Chen RY, Bland L, Chien S: Decrease in cerebral blood flow in rats after experimental subarachnoid hemorrhage: a new animal model. Stroke 16:58-64, 1985
29. Stanimirovic DB, Bertrand N, McCarron R, Uematsu S, Spatz M: Arachidonic acid release and permeability changes induced by endothelins in human cerebromicrovascular endothelium. Acta Neurochir Suppl (Wien) 60:71-75, 1994
30. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, et al: Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 103:9-17, 2005
31. Van Rossum JM: Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn Ther 143:299-330, 1963
32. Vatter H, Weidauer S, Dias S, Preibisch C, Ngone S, Raabe A, et al: Persistence of the nitric oxide-dependent vasodilator pathway of cerebral vessels after experimental subarachnoid hemorrhage. Neurosurgery 60:179-188, 2007
33. Vatter H, Weidauer S, Konczalla J, Dettmann E, Zimmermann M, Raabe A, et al: Time course in the development of cerebral vasospasm after experimental subarachnoid hemorrhage: clinical and neuroradiological assessment of the rat double hemorrhage model. Neurosurgery 58:1190-1197, 2006
34. Vatter H, Zimmermann M, Seifert V, Schilling L: Experimental approaches to evaluate endothelin-A receptor antagonists. Methods Find Exp Clin Pharmacol 26:277-286, 2004
35. Vatter H, Zimmermann M, Tesanovic V, Raabe A, Schilling L, Seifert V: Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: inhibitory effect on endothelin(A) receptor-mediated contraction. J Neurosurg 102:1101-1107, 2005
36. Vatter H, Zimmermann M, Tesanovic V, Raabe A, Seifert V, Schilling L: Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: effect on endothelin(B) receptor-mediated relaxation. J Neurosurg 102:1108-1114, 2005
37. Zimmermann M, Seifert V: Endothelin and subarachnoid hemorrhage: an overview. Neurosurgery 43:863-876, 1998